WSGR logoWSGR logo
WSGR logo
  • Experience
  • People
  • Insights
  • About Us
  • Careers

  • Practice Areas
  • Industries

  • Corporate
  • Intellectual Property
  • Litigation
  • Patents and Innovations
  • Regulatory
  • Technology Transactions

  • Capital Markets
  • Corporate Governance
  • Corporate Life Sciences
  • Derivatives
  • Emerging Companies and Venture Capital
  • Employee Benefits and Compensation
  • Energy and Climate Solutions
  • Executive Advisory Program
  • Finance and Structured Finance
  • Fund Formation
  • Greater China
  • Mergers & Acquisitions
  • Private Equity
  • Public Company Representation
  • Real Estate
  • Restructuring
  • Shareholder Engagement and Activism
  • Tax
  • U.S. Expansion
  • Wealthtech

  • Special Purpose Acquisition Companies (SPACs)

  • Environmental, Social, and Governance

  • AI and Data Center Infrastructure
  • Energy Regulation and Competition
  • Project Development and M&A
  • Project Finance and Tax Credit Transactions
  • Sustainability and Decarbonization
  • Transportation Electrification

  • U.S. Expansion Library and Resources

  • Post-Grant Review
  • Trademark and Advertising

  • Antitrust Litigation
  • Arbitration
  • Board and Internal Investigations
  • Class Action Litigation
  • Commercial Litigation
  • Consumer Litigation
  • Corporate Governance Litigation
  • Employment Litigation
  • Executive Branch Updates
  • Government Investigations
  • Internet Strategy and Litigation
  • Patent Litigation
  • Securities Litigation
  • State Attorneys General
  • Supreme Court and Appellate Practice
  • Trade Secret Litigation
  • Trademark and Copyright Litigation
  • Trial
  • White Collar Crime

  • Advertising, Promotions, and Marketing
  • Antitrust and Competition
  • Committee on Foreign Investment in the U.S. (CFIUS)
  • Communications
  • Data, Privacy, and Cybersecurity
  • Export Control and Sanctions
  • FCPA and Anti-Corruption
  • FDA Regulatory, Healthcare, and Consumer Products
  • Federal Trade Commission
  • Fintech and Financial Services
  • Government Contracts
  • National Security and Trade
  • Payments
  • State Attorneys General
  • Strategic Risk and Crisis Management
  • Tariffs, Customs, and Import Compliance

  • Antitrust and Intellectual Property
  • Antitrust Civil Enforcement
  • Antitrust Compliance and Business Strategy
  • Antitrust Criminal Enforcement
  • Antitrust Litigation
  • Antitrust Merger Clearance
  • European Competition Law
  • Third-Party Merger and Non-Merger Antitrust Representation

  • Anti-Money Laundering
  • Foreign Ownership, Control, or Influence (FOCI)
  • Team Telecom

  • AI in Healthcare
  • Animal Health
  • Artificial Intelligence and Machine Learning
  • Aviation
  • Biotech
  • Blockchain and Cryptocurrency
  • Clean Energy
  • Climate and Clean Technologies
  • Communications and Networking
  • Consumer Products and Services
  • Data Storage and Cloud
  • Defense Tech
  • Diagnostics, Life Science Tools, and Deep Tech
  • Digital Health
  • Digital Media and Entertainment
  • Electronic Gaming
  • Fintech and Financial Services
  • FoodTech and AgTech
  • Global Generics
  • Internet
  • Life Sciences
  • Medical Devices
  • Mobile Devices
  • Mobility
  • NewSpace
  • Quantum Computing
  • Semiconductors
  • Software

  • Offices
  • Country Desks
  • Events
  • Community
  • Our Diversity
  • Sustainability
  • Our Values
  • Board of Directors
  • Management Team

  • Austin
  • Boston
  • Boulder
  • Brussels
  • Century City
  • Hong Kong
  • London
  • Los Angeles
  • New York
  • Palo Alto
  • Salt Lake City
  • San Diego
  • San Francisco
  • Seattle
  • Shanghai
  • Washington, D.C.
  • Wilmington, DE

  • Law Students
  • Judicial Clerks
  • Experienced Attorneys
  • Patent Agents
  • Business Professionals
  • Alternative Legal Careers
  • Contact Recruiting
Stuart A. Williams
Partner
Litigation
swilliams@wsgr.com

D212-497-7705

Download vCard
Open PDF
  • Former Mylan Pharmaceuticals Executive

    Stuart previously served as chief legal officer of leading generic and specialty pharmaceutical company Mylan Pharmaceuticals, where he focused on intellectual property counseling and litigation.

  • Collaborative Global Generics Focus

    With a focus on the firm's global generics practice, Stuart works closely with a variety of practice areas, including litigation, intellectual property, antitrust, FDA/regulatory, corporate, and mergers and acquisitions.

Stuart A. Williams is a partner at Wilson Sonsini Goodrich & Rosati, where he focuses on the global generics practice, working closely with many different practice areas across the firm, including litigation, intellectual property, antitrust, FDA/regulatory, corporate, and mergers and acquisitions.

Prior to joining the firm, Stuart served as chief legal officer of Mylan Pharmaceuticals, one of the world's leading generic and specialty pharmaceutical companies. In this position, Stuart reported directly to the chief executive officer and handled all legal issues affecting both the parent company and its subsidiaries. While he focused on intellectual property counseling and litigation, other key responsibilities included management of and participation in scores of complex trials and appeals, antitrust counseling, arbitration, negotiating and drafting the full spectrum of company agreements, and managing regulatory issues of first impression and government inquiries.

More broadly, Stuart assisted the company's senior management with strategic planning that encompassed the unique combination of product development, litigation tactics, government regulation, partnerships, licensing arrangements, and mergers and acquisitions. He also held oversight of Mylan's human resources function and served as secretary of its board of directors.

Before joining Mylan, Stuart was Of Counsel at DKW Law Group in Pittsburgh. Prior to that, he was a partner at Eckert Seamans Cherin & Mellott, providing outside counsel to clients in a wide variety of industries, including pharmaceuticals, gaming, real estate, manufacturing, sports, entertainment, communications, and healthcare. He also served as the firm's managing director and a member of its board of directors.

Stu previously was involved in several successful business efforts. He served as president of the Washington Trotting Association and Meadows Real Estate, where he was responsible for the day-to-day operations of a racing and gaming facility that was then the largest employer in Washington County, Pennsylvania. Stu also served as a principal advisor to the chairperson and chief executive officer of SG Rehabilitation/SG Speech Associates, a provider of speech, occupational, and physical rehabilitation services to nursing homes, hospitals, and schools.

Experience

Stuart A. Williams is a partner at Wilson Sonsini Goodrich & Rosati, where he focuses on the global generics practice, working closely with many different practice areas across the firm, including litigation, intellectual property, antitrust, FDA/regulatory, corporate, and mergers and acquisitions.

Prior to joining the firm, Stuart served as chief legal officer of Mylan Pharmaceuticals, one of the world's leading generic and specialty pharmaceutical companies. In this position, Stuart reported directly to the chief executive officer and handled all legal issues affecting both the parent company and its subsidiaries. While he focused on intellectual property counseling and litigation, other key responsibilities included management of and participation in scores of complex trials and appeals, antitrust counseling, arbitration, negotiating and drafting the full spectrum of company agreements, and managing regulatory issues of first impression and government inquiries.

More broadly, Stuart assisted the company's senior management with strategic planning that encompassed the unique combination of product development, litigation tactics, government regulation, partnerships, licensing arrangements, and mergers and acquisitions. He also held oversight of Mylan's human resources function and served as secretary of its board of directors.

Before joining Mylan, Stuart was Of Counsel at DKW Law Group in Pittsburgh. Prior to that, he was a partner at Eckert Seamans Cherin & Mellott, providing outside counsel to clients in a wide variety of industries, including pharmaceuticals, gaming, real estate, manufacturing, sports, entertainment, communications, and healthcare. He also served as the firm's managing director and a member of its board of directors.

Stu previously was involved in several successful business efforts. He served as president of the Washington Trotting Association and Meadows Real Estate, where he was responsible for the day-to-day operations of a racing and gaming facility that was then the largest employer in Washington County, Pennsylvania. Stu also served as a principal advisor to the chairperson and chief executive officer of SG Rehabilitation/SG Speech Associates, a provider of speech, occupational, and physical rehabilitation services to nursing homes, hospitals, and schools.

Education
  • J.D., Georgetown University Law Center, 1978Member, Phi Delta Phi honor society; Editor, The Tax Lawyer
  • B.A., Pennsylvania State University, 1975Summa Cum Laude, Phi Beta Kappa
Admissions
  • State Bar of Pennsylvania
Credentials
Education
  • J.D., Georgetown University Law Center, 1978Member, Phi Delta Phi honor society; Editor, The Tax Lawyer
  • B.A., Pennsylvania State University, 1975Summa Cum Laude, Phi Beta Kappa
Admissions
  • State Bar of Pennsylvania

Select Publications

  • Co-author, "FDA's Proposed Rules to Address Inaccurate Orange Book Use Codes May Shorten Approval Timelines for Select 505(b)(2) and Generic Drugs," Generic Pharma 2.0, July 15, 2015
  • Co-author with D.M. Hoffmeister, V. Norviel, J. Guise, P. Munson, D. Carsten, R. Torczon, P. Girinath, and C. Andres, "A Good Opinion Is Worth Its Weight in Gold: Take-Home Lessons for Generic Pharmaceutical Companies to Minimize the Risk of Fee Shifting and Sanctions in the Wake of Highmark and Octane Fitness," Generic Pharma Litigator, January 28, 2015
  • Co-author with D. Hoffmeister, V. Norviel, J. Guise, P. Munson, D. Carsten, R. Torczon, C. Andres, and P. Girinath, "Takeaways for Generics After Octane and Highmark," Law360, September 15, 2014
Insights

Select Publications

  • Co-author, "FDA's Proposed Rules to Address Inaccurate Orange Book Use Codes May Shorten Approval Timelines for Select 505(b)(2) and Generic Drugs," Generic Pharma 2.0, July 15, 2015
  • Co-author with D.M. Hoffmeister, V. Norviel, J. Guise, P. Munson, D. Carsten, R. Torczon, P. Girinath, and C. Andres, "A Good Opinion Is Worth Its Weight in Gold: Take-Home Lessons for Generic Pharmaceutical Companies to Minimize the Risk of Fee Shifting and Sanctions in the Wake of Highmark and Octane Fitness," Generic Pharma Litigator, January 28, 2015
  • Co-author with D. Hoffmeister, V. Norviel, J. Guise, P. Munson, D. Carsten, R. Torczon, C. Andres, and P. Girinath, "Takeaways for Generics After Octane and Highmark," Law360, September 15, 2014
Focus Areas
  • Arbitration
  • Global Generics
  • Litigation
  • people
  • insights
  • about us
  • careers
  • Binder
  • Alumni
  • Mailing List Signup
  • Client FTP Portal
  • Privacy Policy
  • Terms of Use
  • Accessibility
WSGR logo
Twitter
LinkedIn
Facebook
Instagram
Youtube
Copyright © 2026 Wilson Sonsini Goodrich & Rosati. All Rights Reserved.